Tolerability, Safety and Activity of a Muscle Relaxant Molecule IDN5243 in Patients With Low Back Pain
Status:
Withdrawn
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
This is a prospective cohort study, open-label, uncontrolled proof of concept trial. The
trial objective is to evaluate the analgesic tolerability, safety and activity of IDN 5243
(3-glycosyl-3-O-demethylthiocolchicine derivative)administered intramuscularly at 4 mg b.i.d.
for 5 days in the morning (8.00-10.00 AM) and in the evening (6.00-8.00 PM) in subjects with
Low Back Pain (LBP).